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survivalis the key regulator of genes involved in cell cycle progression, cell fate determination, DNA
damage repair and apoptosis. E2F1 is unique in that it contributes both to the control of
cellular proliferation and cellular death. However, the expression of E2F1 protein and its clin-
icopathological associations in patients with NPC are yet to be evaluated. Immunoexpression
of E2F1 was retrospectively assessed in biopsies of 124 consecutive NPC patients without initial
distant metastasis and treated with consistent guidelines. The outcomes were correlated with
clinicopathological features and patient survivals. Results indicated that high E2F1 protein
level (50%) was correlated with primary tumor (p < 0.001) and stage (pZ 0.002; 7th American
Joint Committee on Cancer). In multivariate analyses, high E2F1 expression emerged as an in-
dependent prognosticator for worse disease-specific survival (p Z 0.003), distal metastasis-
free survival (p Z 0.003), and local recurrence-free survival (p Z 0.039). In conclusion, high
E2F1 protein level is common, associated with adverse prognosticators, and might confer tu-
mor aggressiveness through tumor cell proliferation and metastasis.
Copyright ª 2013, Taiwan Genomic Medicine and Biomarker Society. Published by Elsevier
Taiwan LLC. All rights reserved.Introduction
Nasopharyngeal carcinoma (NPC) is an endemic head and
neck epithelial malignancy in Southeastern Asia and
Taiwan; strongly linked to Epstein-Barr virus.1,2 The latter
association is especially authentic for the differentiated
and undifferentiated nonkeratinizing carcinoma types, ac-
cording to current World Health Organization (WHO) tumor
classification, although genetic and environmental factors
also play certain roles in pathogenesis.13 The advances in
diagnostic imaging, radiation therapy, and adjuvant
chemotherapy of NPC have achieved better locoregional
control, whereas it appears less satisfactory in final treat-
ment outcomes.4,5 Despite being an important parameter,
tumor size, nodal status, and metastasis (TNM) staging still
has space to improve in terms of providing the optimal
prognostication to the patients.1,46 Therefore, to identify
potential biomarkers with better correlation to tumor
growth and/or treatment outcomes in patients with NPC,
subsequently, to aid in risk stratification and perhaps
development of therapeutic targets, is indispensable.
The importance of the E2F/retinoblastoma 1 (RB1)
pathway is underlined by its highly evolutionary conservation
across the human,7 and several model organisms.810 In
mammals, E2F activity is generated by a large number of
interconnected complexesdE2Fs (E2F1-8),7,11 transcription
factor Dp family (TFDP1-4)12,13 and three pocket proteins
[RB1, retinoblastoma-like 1 (RBL1, also known as p107), RBL2
(also known as p130)].14 Among E2Fs, E2F1, -2, and -3a are
activators,12,15 whereas E2F3b, E2F4, -5 and -6 are repressors
via recruitment of transcriptional inhibitors such as histone
deacetylase 1 or other chromatin remodeling factors to E2F-
responsive promoters and resulting in transcriptional
repression16,17; E2F7andE2F8, lacking of sequences required
for retinoblastoma 1 (RB1) family protein binding, are E2F1
inhibitors.18 Physically, RB1, RBL1, and RBL2 interact with
E2F1e6 transcription factors appear to be central to their
roles in governing DNA replication.7,1921
The role of E2F1 protein as an oncogene or tumor sup-
pressor is still in debate at the present time.22 The gene
encodes for E2F1 was mapped to 20q11, one chromosomal
region, which is frequently amplified in NPC-derived celllines23,24 and NPC tissue specimens,25,26 suggesting that
E2F1 might play an oncogenic role in patients with NPC.
However, the expression profile of E2F1 in patients with
NPC has not been evaluated. We therefore, aimed to sys-
tematically analyze E2F1 immunoexpression and its asso-
ciations with clinicopathological factors and patient
survivals.
Materials and methods
Patients and tumor specimens
The institutional review board had approved the study by
using formalin-fixed tissue of NPC for this study (IRB201303-
001). Available paraffin-embedded tissue blocks were
retrieved from 124 NPC patients who underwent biopsy
between January 1993 and December 2002. These patients
were free of distant metastasis at initial presentation. The
histological subtypes were reappraised according to the
current WHO classification, and the tumor staging was
re-evaluated with the 7th American Joint Committee on
Cancer (AJCC) system by two pathologists independently.
Immunohistochemical staining and assessment of
E2F1 expression
Tissue sections of 3-mm thickness were cut onto precoated
slides from paraffin-embedded tissue blocks and were next
routinely deparaffinized with xylene and rehydrated with
ethanol washes. Slides were heated by the microwave in a
10mMcitratebuffer (pH6.0) for7minutes to retrieveantigens.
Endogenous peroxidase was blocked with 3% H2O2. Slides were
next washed by Tris-buffered saline for 15 minutes and sub-
sequently incubated with a primary polyclonal antibody tar-
geting E2F1 (No. sc-251, KH95, Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA, USA) at a dilution of 1:100 for 1 hour. Primary
antibodies were detected using the DAKO ChemMate EnVision
Kit (K5001, Carpinteria, CA, USA). The slides were incubated
and developed with the secondary antibody for 30 minutes,
and 3,3-diaminobenzidine for 5 minutes, followed by coun-
terstained using Gill’s Hematoxylin. The immunoexpression of
Table 1 Clinicopathologic features of 124 nasopharyngeal
carcinomas.
Parameters Category n %
Gender
Male 29 23.4
Female 95 76.6
Age (y)
50 80 64.5
51-60 21 16.9
61-70 15 12.1
71-80 7 5.6
81-90 1 1.0
Primary tumor (T)
T1 30 24.2
T2 50 40.3
T3 21 16.9
T4 23 18.5
Nodal status (N)
N0 24 19.4
N1 32 25.8
N2 48 38.7
N3 20 16.1
Stage
I 7 5.6
II 31 25.0
III 46 37.1
IV 40 32.3
Histological grade
Keratinizing 5 4.0
Nonkeratinizing 42 33.9
Undifferentiated 77 62.1
E2F1 overexpression in nasopharyngeal carcinoma 25E2F1was scoredby twopathologists (CFLiandHYHuang)using
a multiheaded microscope to reach a consensus for each case
without prior knowledgeof clinical and follow-up information.
Scoring of E2F1 immunoreactivity was evaluated on the basis
of a combination of both the percentage and intensity of
positively stained tumoral nuclei to generate H-score, which
was calculated using the following equation: H-scoreZ SPi(i
þ1),where i is the intensityof stained tumorcells (0 to4þ) and
Pi is the percentage of stained tumor cells for each intensity
varying from 0% to 100%. Tumor with H-score > median of all
cases was regarded as E2F1 high expression.
Treatment and follow-up
All 124 patients with follow-up for outcome received a
complete course of radiotherapy [RT, total dose 7,000 cGy,
concomitant boost RT (1,800 cGy/day, weeks 1 through 6;
1,600 cGy second daily fraction, weeks 5 through 6] using
Varian 6/100 (DOTmed, Inc., New York, NY, USA) and Clinac
1800 linear accelerator (MedWoW Ltd., Nicosia, Cyprus),
and also cisplatin-based chemotherapy (two cycles of con-
current cisplatin 100 mg/m2 Day 1 and Day 22) in the case
of Stages II-IV diseases, based on the previously published
protocol.27 The method of RT was in general uniform within
this period. All patients were regularly monitored after RT
until death or their last appointment with the mean follow-
up duration being 59.6 months (range: 4-117 months).
Statistical analysis
Statistics were performed using SPSS 14.0 software (SPSS
Inc., Chicago, IL, USA). Chi-square test was used to
compare the E2F1 expression status and various clinico-
pathological parameters. The endpoints analyzed were
disease-specific survival (DSS), distal metastasis-free sur-
vival (DMeFS) and local recurrence-free survival (LRFS),
calculated from the starting date of RT to the date of event
developed. Patients lost to follow-up were censored on the
latest follow-up date. Survival curves were plotted using
the Kaplan-Meier method, and the log-rank test was per-
formed to evaluate prognostic differences between groups.
Multivariate analysis was carried out by the Cox propor-
tional hazards model. However, as a component factor of
the AJCC staging system, primary tumor (T) and nodal
status (N) were not introduced in multivariate comparisons.
For all analyses, two-sided tests of significance were used
with p < 0.05 considered significant.
Results
Immunohistochemical expression of E2F1 and
associations with clinicopathological variables in
NPC specimens
As shown in Table 1, 124 cases of NPC consists of five ker-
atinizing squamous cell carcinomas, 42 nonkeratinizing
differentiated carcinomas, and 77 nonkeratinizing, undif-
ferentiated carcinomas. A total of 95 males and 29 females
with a mean age of 48.6 years (range, 20-83 years) were
included. Seven cases were classified as Stage I, 31 cases asStage II, 46 cases as Stage III, and 40 cases as Stage IV. The
E2F1 immunoexpression was observed and successfully
scored in all cases (nZ 124) with a wide range of positively
stained tumoral nuclei, varying from 5% to 95% (median,
50%). Compared to representative normal tissue (Fig. 1A)
and squamous metaplasia (Fig. 1B), a total of 62 cases with
H < median were therefore classified as low-expressing
group (Fig. 1C); another 62 cases showed H  median
(Fig. 1D). High expression of E2F1 was significantly associ-
ated with NPC cases featuring increment of T3/T4
(p < 0.001) and advanced Stage III/IV (pZ 0.002; Table 2).
However, no association between the E2F1 expression score
and the remaining clinicopathological factors was found.
Prognostic impacts of E2F1 expression in NPC
Patients with NPC more frequently progressed to disease-
specific mortality with advanced T3/T4 (pZ 0.0289), N2/N3
(p Z 0.0008) and Stages III/IV (p Z 0.0020). Whereas the
development of DMeFS and LRFS were significantly associated
with T3/T4 (pZ 0.0085 and pZ 0.0180, respectively), N2/N3
(p Z0.0132 and p Z 0.0160, respectively), and Stages III/IV
(p Z 0.0072 and p Z 0.0026, respectively) with a medium
duration of 21 months for both DMeFS and LRFS. Of note,
E2F1 high expression correlated to a more aggressive clinical
course with a shorter DSS (pZ 0.0001), DMeFS (pZ 0.0001),
and LRFS (p Z 0.0041), respectively (Table 3; Fig. 2). In
Figure 1 Immunoexpression of E2F1 is low in representative normal (A), squamous metaplasia (B), and (C) low-stage nasopha-
ryngeal carcinoma (NPC); however, high in advanced stage (D) of NPC.
26 C.-F. Li et al.multivariate analysis, following tumor stage [p Z 0.027,
hazard ratio (HR) Z 2.202 for DSS; p Z 0.019; HR Z 3.166
for LRFS], high E2F1 expression remained steady as a robustTable 2 Associations between E2F1 expression and other
important clinicopathologic variables.
Parameters Category E2F1
expression
level
p
Low High
Gender
Male 48 47 0.832
Female 14 15
Age (y)
<60 52 46 0.186
 60 years 10 16
Primary tumor (T)
T1-T2 51 29 <0.001*
T3-T4 11 33
Nodal status (N)
N0-N1 33 23 0.071
N2-N3 29 39
Stage
I-II 27 11 0.002*
III-IV 35 51
Histological grade
Keratinizing 1 4 0.161
Nonkeratinizing 25 17
Undifferentiated 36 41
* Statistically significant.prognosticator for three endpoints evaluated and, inde-
pendent portended inferior DSS (p Z 0.003, HR Z 2.353),
DMeFS (p Z 0.003; HR Z 2.624), and LRFS (p Z 0.039;
HR Z 2.072; Table 4). The survival months (mean  SD) of
DSS, DMeFS, and LRFS are also listed in Table 4.
Discussion
In this study, we demonstrate that high E2F1 protein level
can be one potent prognosticator for DSS, DMeFS, and LRFS
in patients with NPC, comparable with what were observed
in other epithelial tumors.2831 For example, in a panel of
87 patients with nonsmall cell lung carcinoma (NSCLC),
increased E2F1 proteins were dramatically associated with
adverse prognosis.28 In another cohort with 127 NSCLCs,
quantitative RT-PCR identified that the overall survival rate
was significantly lower in patients with high-E2F1 tumors
than in those with low-E2F1 tumors.29 Patients with higher
E2F1 protein levels showed a notably shorter disease-
associated survival time in R0 resection cases in pancre-
atic ductal carcinomas.30 Besides, high E2F1 expression in
patients with breast cancer displayed significantly worse
survival.31 Indeed, NPC might differ from other epithelial
cancers in its etiology, epidemiology, and potential thera-
peutic options; despite having a cure for the majority of the
patients, challenges still exist in the prevention of recur-
rence and treatment of patients with refractory or meta-
static NPC.32 Therefore, identifying biomarkers indepen
dently correlated with tumor aggressiveness to facilitate
appropriate allocation of adjuvant therapy will be valuable
for patient-tailored strategies to manage high-risk NPCs.33
We accordingly speculate that E2F1 might not only be a
Table 3 Univariate log-rank analyses.
Parameters Category n DSS DMeFS LRFS
n p n p n p
Gender
Male 95 45 0.7870 38 0.6128 30 0.3240
Female 29 14 11 7
Age (years)
<60 98 48 0.8600 42 0.3091 29 0.8206
60 26 11 7 8
Primary tumor (T)
T1-T2 80 32 0.0289* 25 0.0085* 19 0.0180*
T3-T4 44 27 24 18
Nodal status (N)
N0-N1 56 18 0.0008* 17 0.0132* 12 0.0160*
N2-N3 68 41 32 25
Stage
I-II 38 10 0.0020* 9 0.0072* 5 0.0026*
III-IV 86 49 40 32
Histological grade
Keratinizing/non-keratinizing 47 20 0.1980 17 0.2753 15 0.9521
Undifferentiated 77 39 32 22
E2F1 expression Low (H-score < median) 62 19 0.0001* 15 0.0001* 13 0.0041*
High (H-score  median) 62 40 34 24
DMeFS Z distal metastasis-free survival; DSS Z disease-specific survival; LRFS Z local recurrence-free survival.
* Statistically significant.
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patient with NPC.
Significantly increased hazard ratios of DSS, DMeFS, and
LRFS in NPC patients with higher stages, III-IV, were further
ascertained, analogous to other studies.34,35 In conjunction
withmeaningful correlations between the E2F1 protein level
and both primary tumor and stage, we therefore suggest that
high E2F1 protein might contribute to the tumor cell prolif-
eration and metastasis in at least a subset of patients with
NPC. Consistent with the results in this NPC cohort, upregu-
lation of E2F1 protein has been identified in several types
of tumor and is correlatedwith tumor cell proliferation, such
as lung cancers,28,29,36 osteosarcoma,37 and squamous cell
carcinoma of the oesophagus.38,39 In these cases, E2F1 pro-
tein overexpression in neuroendocrine lung tumors was
drastically associated with a high Ki-67 proliferative index
and the B-cell CLL, lymphoma 2/BCL2-associated X protein
ratio (BCL2/BAX > 1).36 Because BLC2 and BAX are anti- and
proapoptotic regulators, respectively, E2F1 apparently
plays an oncogenic role. Likewise, high E2F1 immunostain-
ings demonstrated a radical increase in their indexes of the
proliferating cell nuclear antigen (PCNA) in NSCLCs.28 Sig-
nificant correlation has also been detected between the
mRNA levels of E2F1 and thymidylate synthase (TYMS )29;
the latter encodes the enzyme used to generate thymidine
monophosphate and is subsequently phosphorylated to
thymidine triphosphate for use in DNA synthesis and
repair.40,41 In these NPC patients, we lately uncovered that
high TYMS protein levels can serve as an independent prog-
nosticator for inferior DSS, DMeFS, and LRFS, strengthens the
underlyingmolecular relationship between E2F1 and TYMS in
patients with NPC. In cellular and/or animal models, stable
transfection of E2F1 gene into low invasive, head and neckcarcinoma-derived cell lines with low expression of E2F1
dramatically induced their invasive ability.42 Moreover, pri-
mary rat embryo cells that were transfected with E2F1 and
TFDP1 form colonies in soft agar and induce tumor formation
in nude mice.43 Overexpression of E2F1 in rat embryonic fi-
broblasts leads to neoplastic transformation.44 Lentivirus-
mediated RNA interference targeting E2F1 inhibits human
gastric cancer MGC-803 cell growth through upregulation of
phosphatase and tensin homolog (also known as PTEN),
caspase-3 and -9 expression levels and downregulation of
nuclear factor kappa B in a mice xenograft model.45 Mice
implanted with metastatic SK-Mel-147 melanoma cells
expressing E2F1 short hairpin RNA had a significantly smaller
area of metastases per lung than controls.46 Therefore,
findings from clinical associations, cellular, and animal
models support our results.
Nevertheless, overexpression of E2F1 was also substan-
tially associated with increased disease-free survival in
squamous cell carcinoma of the anterior tongue.47 In human
colorectal adenocarcinomas, the relation between E2F1
expression level and apoptosis was drastically correlated.48
Nuclear E2F1 expression was significantly and inversely
correlated with phospho-RB1 and positively related to tumor
apoptotic index in patients with hepatocellular carcinoma.49
Low E2F1 transcript levels are a strong determinant of
favorable breast cancer outcome, with low risk ofmetastasis
irrespective of estrogen receptor status.50 Furthermore,
E2F1 overexpression correlates with decreased proliferation
and better prognosis in adenocarcinomas of Barrett esoph-
agus.51 In most cellular models, high E2F1 levels exerted the
growth-suppressing or proapoptotic effect, including Yes-4
and Yes-6 cells of esophageal cancer,52 MKN-45 cells of
gastric carcinoma,53 and osteosarcoma-derived Saos2 cells.54
Figure 2 Kaplan-Meier plots show that advanced primary tumor (T3-T4; A, E, I), nodal status (N2-N3; B, F, J), and stage (III-IV; C,
G, K), as well as E2F1 high expression (D, H, L) impact significantly inferior prognostic outcomes in disease-specific survival (A-D),
distal metastasis-free survival (E-H), and local recurrence-free survival (I-L).
28 C.-F. Li et al.However, these observations are not completely controver-
sial because E2F1 was recognized as a sturdy regulator of
apoptosis upon DNA damage in all human cancer types orig-
inally.55 Hypophosphorylated (active) RB1 binds E2F1 and
thereby downregulates E2F1 activity, suggesting a model in
which RB1 restricts cell cycle progression by restraining
E2F1.7,14,56
It has been shown that tumor cells, especially from
advanced lesions, exhibit severe defects in the cell death
pathways that are normally activated by E2F1, which may
otherwise select against apoptotic consequences of deregu-
lated E2F1 in the absence of RB1.57 Whether the balance of
E2F1 activity in a specific tissue inhibits or promotes tumori-
genesis is most likely dependent upon the background of pro
versus anti-aporpotic signals received by cells at a given
time.58 Transactivation of E2F1 target genes, TYMS, dihy-
drofolate reductase, PCNA, ribonucleotide reductase M1,cyclin E1, cyclindependent kinase 1, myeloblastosis viral
oncogene homolog (avian)-like 2,59,60 and stathmin 1,61 that
participate in the processes of angiogenesis, invasion, and
metastasis, alongwith significantly higher E2F1 protein levels
wereexpressed in advanced lesionswith large tumor size (T3-
T4) and progressive stage (Stages III-IV) in this NPC cohort,
reinforce the view that E2F1 plays a central role in many as-
pects of NPC development.62
Taken together, prognostic evaluation of E2F1 protein
level in a well-characterized, large series of NPC were
performed. The E2F1 was detectable by immunohisto-
chemistry in the vast majority of NPC but shows a wide
range of distribution in expression level, as assessed by H-
score. Along with higher tumor stage, E2F1 overexpression
is independently predictive of DSS, DMeFS, and LRFS,
additionally, which might represent a useful prognostic
adjunct to better stratify the prognosis of NPC cases.
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